Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Pediatr Dermatol ; 30(3): e18-9, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-22747743

RESUMO

We present the case of a 9-day-old girl with venous dilatations in lower abdomen and legs associated to cyanosis. Radiological studies revealed a congenital agenesis of the entire inferior vena cava.


Assuntos
Veia Ilíaca/anormalidades , Pele/irrigação sanguínea , Pele/patologia , Malformações Vasculares/patologia , Veia Cava Inferior/anormalidades , Feminino , Humanos , Veia Ilíaca/patologia , Recém-Nascido , Imageamento por Ressonância Magnética , Veia Cava Inferior/patologia
3.
Joint Bone Spine ; 79(5): 510-3, 2012 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-22857979

RESUMO

Anti-tumour necrosis factor-alpha (TNF-α) agents are effective drugs used in several chronic inflammatory diseases such as rheumatoid arthritis (RA). Psoriasiform lesions, including palmoplantar pustulosis, have been described following anti-TNF-α therapy. These lesions often resolve with topical therapy with or without discontinuation of these drugs. However, in some cases, psoriasiform lesions may persist despite anti-TNF-α withdrawal. We report on two RA patients treated with adalimumab (ADA) who developed palmoplantar pustular despite dermatological treatment and ADA discontinuation. Tocilizumab (TCZ) therapy was initiated because of persistence of skin lesions and flare of the disease. Following treatment with this drug, complete resolution of the dermatological lesions and induction of remission of RA was achieved. To the best of our knowledge, management of palmoplantar pustulosis due to TNF-α agents with TCZ leading to both improvement of the disease and resolution of the cutaneous lesions has not previously been reported.


Assuntos
Anticorpos Monoclonais Humanizados/efeitos adversos , Anticorpos Monoclonais Humanizados/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Psoríase/induzido quimicamente , Psoríase/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adalimumab , Adulto , Anticorpos Monoclonais/farmacologia , Anticorpos Monoclonais/uso terapêutico , Anticorpos Monoclonais Humanizados/farmacologia , Feminino , Humanos , Pessoa de Meia-Idade , Psoríase/diagnóstico , Receptores de Interleucina-6/antagonistas & inibidores , Receptores de Interleucina-6/efeitos dos fármacos , Resultado do Tratamento , Suspensão de Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...